Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependencySarah Aminov, Amit Verma, Srinivas Aluri et al.|Journal of Clinical Investigation|2024Cited by 20
Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact OutcomesMalika Kapadia, Seth J. Rotz, Leslie Lehmann et al.|Transplantation and Cellular Therapy|2022Cited by 16
Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantationMariah L. Wright, Rajinder Bajwa, Hemalatha G. Rangarajan et al.|Pediatric Transplantation|2021Cited by 4
Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling InhibitionSarah Aminov, Amit Verma, Orsi Giricz et al.|Blood|2022Cited by 3
Defining Patient-Important Outcomes after Pediatric Hematopoietic Stem Cell Transplant: A Transplant Associated Learning Network Team (TALNT) Pilot ProjectTaylor Fitch, Christopher E. Dandoy, Gabe Usleaman et al.|Transplantation and Cellular Therapy|2021Cited by 0